JP2001515075A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001515075A5 JP2001515075A5 JP2000509705A JP2000509705A JP2001515075A5 JP 2001515075 A5 JP2001515075 A5 JP 2001515075A5 JP 2000509705 A JP2000509705 A JP 2000509705A JP 2000509705 A JP2000509705 A JP 2000509705A JP 2001515075 A5 JP2001515075 A5 JP 2001515075A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- chloro
- pharmaceutically acceptable
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 description 18
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- XXLFLUJXWKXUGS-UHFFFAOYSA-N 6-methoxyquinoline-4-carboxylic acid Chemical compound N1=CC=C(C(O)=O)C2=CC(OC)=CC=C21 XXLFLUJXWKXUGS-UHFFFAOYSA-N 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- VOIKVWNNWDFFMQ-UHFFFAOYSA-N 1-(4-chlorophenyl)-3-(7-chloroquinolin-4-yl)urea Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=NC2=CC(Cl)=CC=C12 VOIKVWNNWDFFMQ-UHFFFAOYSA-N 0.000 description 1
- JQCZOECASVNHMQ-UHFFFAOYSA-N 1-(7-chloroquinolin-4-yl)-3-(3,4,5-trimethoxyphenyl)urea Chemical compound COC1=C(OC)C(OC)=CC(NC(=O)NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 JQCZOECASVNHMQ-UHFFFAOYSA-N 0.000 description 1
- CTZRSKUIEVVAJG-UHFFFAOYSA-N 1-(7-chloroquinolin-4-yl)-3-(4-methoxyphenyl)urea Chemical compound C1=CC(OC)=CC=C1NC(=O)NC1=CC=NC2=CC(Cl)=CC=C12 CTZRSKUIEVVAJG-UHFFFAOYSA-N 0.000 description 1
- RETJOGPFTCSHIR-UHFFFAOYSA-N 1-[3-chloro-4-(trifluoromethyl)phenyl]-3-(5-nitroquinolin-4-yl)urea Chemical compound C=12C([N+](=O)[O-])=CC=CC2=NC=CC=1NC(=O)NC1=CC=C(C(F)(F)F)C(Cl)=C1 RETJOGPFTCSHIR-UHFFFAOYSA-N 0.000 description 1
- ORRPEZHMWMSQGQ-UHFFFAOYSA-N 1-[3-chloro-4-(trifluoromethyl)phenyl]-3-quinolin-4-ylurea Chemical compound C1=C(Cl)C(C(F)(F)F)=CC=C1NC(=O)NC1=CC=NC2=CC=CC=C12 ORRPEZHMWMSQGQ-UHFFFAOYSA-N 0.000 description 1
- OPSKCKQXDKZQBK-UHFFFAOYSA-N 1-isoquinolin-1-yl-3-(1-methylindol-5-yl)urea Chemical compound C1=CC=C2C(NC(=O)NC=3C=C4C=CN(C4=CC=3)C)=NC=CC2=C1 OPSKCKQXDKZQBK-UHFFFAOYSA-N 0.000 description 1
- QEJVAJGAMCJITG-UHFFFAOYSA-N 5-chloroquinoline-4-carboxylic acid Chemical compound C1=CC(Cl)=C2C(C(=O)O)=CC=NC2=C1 QEJVAJGAMCJITG-UHFFFAOYSA-N 0.000 description 1
- ZRYMLJGLNAOPNK-UHFFFAOYSA-N 6-chloroquinoline-4-carboxylic acid Chemical compound C1=C(Cl)C=C2C(C(=O)O)=CC=NC2=C1 ZRYMLJGLNAOPNK-UHFFFAOYSA-N 0.000 description 1
- SUCSQKWIHAXNTM-UHFFFAOYSA-N 6-ethoxyquinoline-4-carboxylic acid Chemical compound N1=CC=C(C(O)=O)C2=CC(OCC)=CC=C21 SUCSQKWIHAXNTM-UHFFFAOYSA-N 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- TXYVRYRRTQYTHJ-UHFFFAOYSA-N 7-chloroquinoline-4-carboxylic acid Chemical compound ClC1=CC=C2C(C(=O)O)=CC=NC2=C1 TXYVRYRRTQYTHJ-UHFFFAOYSA-N 0.000 description 1
- QIRLJMJLJXBUMP-UHFFFAOYSA-N 7-fluoroquinoline-4-carboxylic acid Chemical compound FC1=CC=C2C(C(=O)O)=CC=NC2=C1 QIRLJMJLJXBUMP-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9717178.9A GB9717178D0 (en) | 1997-08-14 | 1997-08-14 | Compounds |
| GB9717178.9 | 1997-08-14 | ||
| GBGB9807756.3A GB9807756D0 (en) | 1998-04-08 | 1998-04-08 | Compounds |
| GB9807756.3 | 1998-04-08 | ||
| PCT/GB1998/002437 WO1999009024A1 (en) | 1997-08-14 | 1998-08-13 | Phenyl urea and phenyl thiourea derivatives as hfgan72 antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2001515075A JP2001515075A (ja) | 2001-09-18 |
| JP2001515075A5 true JP2001515075A5 (enExample) | 2006-01-05 |
Family
ID=26312063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000509705A Withdrawn JP2001515075A (ja) | 1997-08-14 | 1998-08-13 | Ｈｆｇａｎ７２アンタゴニストとしてのフェニルウレアおよびフェニルチオウレア誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6410529B1 (enExample) |
| EP (1) | EP1003737A1 (enExample) |
| JP (1) | JP2001515075A (enExample) |
| AR (1) | AR016817A1 (enExample) |
| AU (1) | AU8741198A (enExample) |
| CA (1) | CA2300178A1 (enExample) |
| WO (1) | WO1999009024A1 (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| ATE300521T1 (de) | 1996-09-25 | 2005-08-15 | Astrazeneca Ab | Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern |
| US5935814A (en) * | 1997-04-30 | 1999-08-10 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72Y receptor |
| US6020157A (en) * | 1997-04-30 | 2000-02-01 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72X receptor |
| US6653086B1 (en) | 1998-04-14 | 2003-11-25 | Arena Pharmaceuticals, Inc. | Endogenous constitutively activated G protein-coupled orphan receptors |
| ES2196806T3 (es) * | 1998-05-08 | 2003-12-16 | Smithkline Beecham Plc | Derivados de fenilurea y de feniltiourea. |
| US6420563B1 (en) | 1998-07-31 | 2002-07-16 | Arena Pharmaceuticals, Inc. | Small molecule modulators of G protein-coupled receptor six |
| EP1142868A4 (en) * | 1998-12-22 | 2004-09-29 | Mitsubishi Chem Corp | AMIDE DERIVATIVES |
| WO2000047576A1 (en) * | 1999-02-12 | 2000-08-17 | Smithkline Beecham Plc | Cinnamide derivatives as orexin-1 receptors antagonists |
| AU2804400A (en) | 1999-02-12 | 2000-08-29 | Smithkline Beecham Plc | Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists |
| US6596730B1 (en) | 1999-02-12 | 2003-07-22 | Smithkline Beecham P.L.C. | Phenyl urea and phenyl thiourea derivatives |
| EP1150664B1 (en) * | 1999-02-12 | 2003-05-28 | SmithKline Beecham plc | Novel use of orexin receptor antagonists |
| WO2001062765A2 (en) * | 1999-02-26 | 2001-08-30 | Arena Pharmaceuticals, Inc. | Small molecule modulators of g protein-coupled receptor six |
| IL147280A0 (en) | 1999-07-07 | 2002-08-14 | Astrazeneca Uk Ltd | Quinazoline derivatives |
| EP1242339B1 (en) * | 1999-09-29 | 2009-07-29 | Nerviano Medical Sciences S.r.l. | Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules |
| US6677160B1 (en) | 1999-09-29 | 2004-01-13 | Pharmacia & Upjohn Company | Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules |
| US6764858B2 (en) | 1999-09-29 | 2004-07-20 | Pharmacia & Upjohn Company | Methods for creating a compound library |
| KR100881105B1 (ko) | 1999-11-05 | 2009-02-02 | 아스트라제네카 아베 | Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체 |
| DE60112268T2 (de) | 2000-03-06 | 2006-05-24 | Astrazeneca Ab | Verwendung von quinazolinderivate als inhibitoren der angiogenese |
| CN100393703C (zh) | 2000-03-14 | 2008-06-11 | 埃科特莱茵药品有限公司 | 1,2,3,4-四氢异喹啉的衍生物 |
| DE60121931T2 (de) | 2000-04-07 | 2007-03-01 | Astrazeneca Ab | Chinazolinverbindungen |
| JPWO2001085693A1 (ja) | 2000-05-11 | 2004-01-08 | 萬有製薬株式会社 | Ｎ−アシルテトラヒドロイソキノリン誘導体 |
| WO2001096302A1 (en) * | 2000-06-16 | 2001-12-20 | Smithkline Beecham P.L.C. | Piperidines for use as orexin receptor antagonists |
| AU7425801A (en) | 2000-06-24 | 2002-01-08 | Astrazeneca Ab | Guanidine derivatives of quinazoline and quinoline for use in the treatment of autoimmune diseases |
| AU2002216758A1 (en) * | 2000-07-03 | 2002-01-14 | Astrazeneca Ab | Quinazolines with therapeutic use |
| CA2432809C (en) | 2000-12-21 | 2010-11-30 | Schering Corporation | Heteroaryl urea neuropeptide y y5 receptor antagonists |
| US6946476B2 (en) | 2000-12-21 | 2005-09-20 | Schering Corporation | Heteroaryl urea neuropeptide Y Y5 receptor antagonists |
| CA2446396A1 (en) | 2001-05-05 | 2002-11-14 | Smithkline Beecham P.L.C. | N-aroyl cyclic amines |
| KR20040029326A (ko) | 2001-06-28 | 2004-04-06 | 스미스클라인비이참피이엘시이 | 오렉신 수용체 길항제로서의 ｎ-아로일 시클릭 아민 유도체 |
| GB0115862D0 (en) * | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| NZ538029A (en) | 2002-07-09 | 2006-08-31 | Actelion Pharmaceuticals Ltd | 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives |
| JP2006505533A (ja) * | 2002-09-17 | 2006-02-16 | アクテリオン ファマシューティカルズ リミテッド | １−ピリジン−４−イル−尿素誘導体 |
| WO2004033418A2 (en) | 2002-10-11 | 2004-04-22 | Actelion Pharmaceuticals Ltd. | Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists |
| GB0230195D0 (en) * | 2002-12-24 | 2003-02-05 | Biofocus Plc | Compound Libraries |
| AU2003295158A1 (en) * | 2002-12-24 | 2004-07-22 | Biofocus Plc | Compound libraries of 1,3,5-substitute indazole derivatives as compounds for targetting compounds capable of binding to the g-protein coupled receptor |
| JP2006521345A (ja) * | 2003-03-28 | 2006-09-21 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | ニコチン性アセチルコリン受容体の正のアロステリック調節剤 |
| US20050026844A1 (en) | 2003-04-03 | 2005-02-03 | Regents Of The University Of California | Inhibitors for the soluble epoxide hydrolase |
| WO2004096767A1 (en) * | 2003-04-25 | 2004-11-11 | H. Lundbeck A/S | Sustituted indoline and indole derivatives |
| US7538109B2 (en) | 2003-04-28 | 2009-05-26 | Actelion Pharmaceuticals Ltd | Quinoxalin-3-one derivatives as orexin receptor antagonists |
| BRPI0508263B8 (pt) | 2004-03-01 | 2021-05-25 | Idorsia Pharmaceuticals Ltd | derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina |
| EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US7550499B2 (en) * | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
| BRPI0515991A (pt) * | 2004-10-13 | 2008-08-19 | Merck Patent Gmbh | derivados de bisariluréia substituìda heterocìclica como inibidores de cinase |
| CA2584342C (en) | 2004-10-20 | 2013-04-30 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| US7501395B2 (en) | 2005-04-25 | 2009-03-10 | Eisai R & D Management Co., Ltd. | Method of screening for antianxiety drugs |
| AR059826A1 (es) * | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| JP2009543785A (ja) | 2006-07-14 | 2009-12-10 | メルク エンド カムパニー インコーポレーテッド | 架橋ジアゼパンオレキシン受容体アンタゴニスト |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| WO2008101030A1 (en) * | 2007-02-13 | 2008-08-21 | The Regents Of The University Of California | Methods for amplifying steroid hormone effects |
| JP2010527924A (ja) | 2007-05-18 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | オキソ架橋ジアゼパンオレキシン受容体アンタゴニスト |
| US8030495B2 (en) | 2007-05-23 | 2011-10-04 | Coleman Paul J | Cyclopropyl pyrrolidine orexin receptor antagonists |
| ES2379744T3 (es) | 2007-05-23 | 2012-05-03 | Merck Sharp & Dohme Corp. | Antagonistas de piridil-piperidina de los receptores de orexinas |
| EP2318367B1 (en) * | 2008-04-30 | 2013-03-20 | Actelion Pharmaceuticals Ltd. | Piperidine and pyrrolidine compounds |
| EP2370427A1 (en) | 2008-12-02 | 2011-10-05 | Glaxo Group Limited | N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and uses thereof |
| GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| CA2751886C (en) * | 2009-02-11 | 2017-08-29 | Merck Patent Gmbh | Novel amino azaheterocyclic carboxamides |
| KR20120007061A (ko) | 2009-04-24 | 2012-01-19 | 글락소 그룹 리미티드 | 오렉신 길항제로서 사용되는 3-아자비시클로［4.1.0］헵탄 |
| US20120149711A1 (en) | 2009-08-24 | 2012-06-14 | Glaxo Group Limited | Piperidine derivatives used as orexin antagonists |
| WO2011023578A1 (en) | 2009-08-24 | 2011-03-03 | Glaxo Group Limited | 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| EP2528604B1 (en) | 2010-01-29 | 2017-11-22 | The Regents of the University of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| PE20130211A1 (es) | 2010-04-02 | 2013-03-22 | Senomyx Inc | Modificador del sabor dulce |
| EP2598497B1 (en) * | 2010-07-29 | 2019-03-06 | Merck Patent GmbH | Cyclic amine azaheterocyclic carboxamides |
| UA110113C2 (xx) * | 2010-07-29 | 2015-11-25 | Біциклічні азагетероциклічні карбоксаміди | |
| WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
| WO2012089607A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors |
| SG10201606309WA (en) | 2011-08-12 | 2016-09-29 | Senomyx Inc | Sweet flavor modifier |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| US11339128B2 (en) | 2014-11-07 | 2022-05-24 | Firmenich Incorporated | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers |
| BR112018015389B1 (pt) | 2016-03-17 | 2023-12-19 | F. Hoffmann-La Roche Ag | Derivado de 5-etil-4-metil-pirazol-3-carboxamida, seu processo de fabricação, preparação farmacêutica oral e uso |
| EP3937919A4 (en) | 2019-03-14 | 2023-04-12 | Board of Regents, The University of Texas System | SMALL MOLECULES GRB2 STABILIZER FOR INHIBITION OF RAS-MAP KINASE |
| JP2023513241A (ja) * | 2020-02-12 | 2023-03-30 | キュラデブ ファーマ ピーブイティー． リミテッド | 小分子ｓｔｉｎｇアンタゴニスト |
| CN120187710A (zh) * | 2023-09-28 | 2025-06-20 | 四川大学华西医院 | 一种含苯环的具有镇痛功效的化合物及其制备方法和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4009020A (en) * | 1975-05-06 | 1977-02-22 | Amchem Products, Inc. | Method of regulating plant growth |
| US5552411A (en) | 1995-05-26 | 1996-09-03 | Warner-Lambert Company | Sulfonylquinolines as central nervous system and cardiovascular agents |
| US5731315A (en) | 1995-06-07 | 1998-03-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds |
| DK0944386T3 (da) | 1996-12-13 | 2003-01-27 | Aventis Pharma Inc | Sulfonsyre- eller sulfonylamino-N-(heteroaralkyl)-azaheterocyclylamid-forbindelser |
-
1998
- 1998-08-12 AR ARP980104002A patent/AR016817A1/es unknown
- 1998-08-13 WO PCT/GB1998/002437 patent/WO1999009024A1/en not_active Ceased
- 1998-08-13 EP EP98938812A patent/EP1003737A1/en not_active Withdrawn
- 1998-08-13 CA CA002300178A patent/CA2300178A1/en not_active Abandoned
- 1998-08-13 AU AU87411/98A patent/AU8741198A/en not_active Abandoned
- 1998-08-13 US US09/485,623 patent/US6410529B1/en not_active Expired - Fee Related
- 1998-08-13 JP JP2000509705A patent/JP2001515075A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001515075A5 (enExample) | ||
| JP2003522101A5 (enExample) | ||
| JP2002536445A5 (enExample) | ||
| CA2378243A1 (en) | Methods for treating or preventing pain and anxiety | |
| JP2001247459A5 (enExample) | ||
| JP2001526218A5 (enExample) | ||
| KR920006335A (ko) | 안지오텐신 ⅱ수용체 길항제 | |
| RU2003134544A (ru) | Амиды антраниловой кислоты, способы их получения, их применение в качестве антиаритмических средств, а также содержащие их фармацевтические композиции | |
| JP2003506388A5 (enExample) | ||
| JP2002525286A5 (enExample) | ||
| JP2003503385A5 (enExample) | ||
| KR920700200A (ko) | 19-노르-비타민 d 화합물 | |
| JP2005519908A5 (enExample) | ||
| RU2001133004A (ru) | Применение селективных антагонистов альфа1b-адренергического рецептора для улучшения состояния при сексуальной дисфункции | |
| CA2405796A1 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| JP2005507938A5 (enExample) | ||
| EP0575749A2 (en) | Use of potassium-channel activators for the manufacture of a medicament for the treatment of gastrointertinal ulcers | |
| JP2002527414A5 (enExample) | ||
| RU99127433A (ru) | Эрголиновые производные и их применение в качестве антагонистов рецепторов соматостатина | |
| JP2005511594A5 (enExample) | ||
| RU98119076A (ru) | Производные 2-(3h)-оксазолона и их применение в качестве ингибиторов сох-2 | |
| JP2002509858A5 (enExample) | ||
| JP2005514370A5 (enExample) | ||
| TNSN05080A1 (en) | NOVEL ANTIMYCOBACTERIAL COMPOUNDS (as filed) AND PYRROLE DERIVATIVES AS ANTIMYCOBACTERIAL COMPOUNDS (as published) | |
| JP2008508365A5 (enExample) |